Trek Financial LLC Increases Position in Thermo Fisher Scientific Inc. $TMO

Trek Financial LLC increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 40.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,091 shares of the medical research company’s stock after purchasing an additional 896 shares during the quarter. Trek Financial LLC’s holdings in Thermo Fisher Scientific were worth $1,499,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Thermo Fisher Scientific by 0.9% in the 2nd quarter. Vanguard Group Inc. now owns 33,789,164 shares of the medical research company’s stock worth $13,700,154,000 after buying an additional 309,207 shares during the last quarter. Norges Bank purchased a new position in Thermo Fisher Scientific in the second quarter worth $2,264,615,000. Franklin Resources Inc. lifted its holdings in shares of Thermo Fisher Scientific by 11.3% during the 2nd quarter. Franklin Resources Inc. now owns 4,897,546 shares of the medical research company’s stock valued at $1,985,759,000 after purchasing an additional 498,238 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Thermo Fisher Scientific by 2.6% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 3,000,562 shares of the medical research company’s stock worth $1,216,612,000 after purchasing an additional 74,971 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA increased its position in Thermo Fisher Scientific by 25.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,936,998 shares of the medical research company’s stock valued at $1,424,503,000 after buying an additional 594,218 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In other news, EVP Frederick M. Lowery sold 6,913 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $597.68, for a total transaction of $4,131,761.84. Following the completion of the transaction, the executive vice president directly owned 14,367 shares of the company’s stock, valued at $8,586,868.56. The trade was a 32.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Lisa P. Britt sold 10,225 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $571.62, for a total transaction of $5,844,814.50. Following the sale, the vice president directly owned 14,145 shares in the company, valued at $8,085,564.90. This trade represents a 41.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 131,767 shares of company stock valued at $76,467,793 in the last 90 days. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Down 2.2%

NYSE:TMO opened at $625.42 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The company’s fifty day moving average price is $590.88 and its 200-day moving average price is $531.60. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $643.99. The firm has a market capitalization of $234.98 billion, a P/E ratio of 36.13, a PEG ratio of 4.12 and a beta of 0.91.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, beating the consensus estimate of $5.50 by $0.29. The company had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The firm’s revenue was up 4.9% on a year-over-year basis. During the same period in the prior year, the company earned $5.28 earnings per share. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific announced that its board has initiated a stock repurchase program on Thursday, November 6th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase up to 2.4% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, January 15th. Stockholders of record on Monday, December 15th were paid a $0.43 dividend. The ex-dividend date was Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.94%.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on TMO. UBS Group raised their price target on Thermo Fisher Scientific from $500.00 to $590.00 and gave the stock a “neutral” rating in a report on Thursday, October 23rd. Stifel Nicolaus boosted their target price on shares of Thermo Fisher Scientific from $583.00 to $700.00 and gave the stock a “buy” rating in a research report on Friday, January 9th. Morgan Stanley raised their price target on shares of Thermo Fisher Scientific from $656.00 to $670.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. Citigroup raised shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $580.00 to $660.00 in a report on Thursday, December 11th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $625.47.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.